NTRK1 and thyroid cancer: The efficacy of larotrectinib, a highly selective TRK inhibitor targeting TRKA, TRKB, and TRKC, was examined in phase 1 and 2 clinical trials, in 17 different TRK fusion-positive cancer types, including thyroid cancer.